Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and MSCs for Primary Nephrotic Syndrome with CKD 3-4
NCT02966717Phase 2Unknown
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Stem Cell Therapies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab and mesenchymal stem cells in chronic kidney disease (CKD) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoints: The change of serum creatinine elevation at 12 weeks and The percentage of end-stage renal disease or death at 3 years. Status: unknown.
02
Drugs
rituximabmesenchymal stem cells
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02966717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966717.